日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity

Dabogratinib (TYRA-300)，一种FGFR3亚型选择性抑制剂：抗肿瘤活性的临床前和初步临床证据

期刊:Molecular Cancer Therapeutics
影响因子:5.5
doi:10.1158/1535-7163.MCT-25-0652
Starrett, Jacqueline H; Allen, Eric L; Neal, Melissa; Iyer, Samhita; Ye, Qing; Hudkins, Robert L; Degaonkar, Viraj; Lihou, Christine; Swanson, Ronald V; Boni, Valentina; Fuentes-Antrás, Jesús; Pobel, Cedric; Loriot, Yohann; Zalutskaya, Alena; Goluboff, Erik
FGFR3
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

阿特珠单抗单药治疗转移性尿路上皮癌：II期IMvigor210试验的最终分析

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103972
Rosenberg, J E; Galsky, M D; Powles, T; Petrylak, D P; Bellmunt, J; Loriot, Y; Necchi, A; Hoffman-Censits, J; Perez-Gracia, J L; van der Heijden, M S; Dreicer, R; Durán, I; Castellano, D; Drakaki, A; Retz, M; Sridhar, S S; Grivas, P; Yu, E Y; O'Donnell, P H; Burris, H A; Mariathasan, S; Shi, Y; Goluboff, E; Bajorin, D
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma

确定转移性尿路上皮癌患者接受度伐利尤单抗或度伐利尤单抗联合曲美利木单抗治疗后长期生存的预测特征

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-023-11380-6
Alt, Marie; Stecca, Carlos; Lin, Yian; Kazeem, Gbenga; Goluboff, Erik T; Sridhar, Srikala S
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

The effects of aging, arteriosclerosis, and hypertension upon the cerebral circulation

衰老、动脉硬化和高血压对脑循环的影响

期刊:Journal of Clinical Investigation
影响因子:13.6
doi:10.1172/JCI102760
SHENKIN, H A; NOVAK, P; GOLUBOFF, B; SOFFE, A M; BORTIN, L
高血压
心血管
神经科学
衰老
动脉粥样硬化
发表日期：1953
文献求助 收藏